PET imaging in a longitudinal non-Hodgkin's lymphoma study: Association with tumor volume

Acta Radiologica

Volumn 52, Issue 9, 2011, Pages 995-1002

  Rossi, Maija ^a   Korkola, Pasi ^a   Pertovaara, Hannu ^a   Järvenpää, Ritva ^a   Dastidar, Prasun ^a,b   Wu, Xingchen ^a   Soimakallio, Seppo ^a,b   Eskola, Hannu ^a,c   Kellokumpu Lehtinen, Pirkko Liisa ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

CT; Lymphoma; MR imaging; PET; Segmentation

Indexed keywords

ABSOLUTE VALUES; AFTER-TREATMENT; CELL PROLIFERATION RATE; CLINICAL CHARACTERISTICS; CLINICAL EXAMINATION; COMPUTED TOMOGRAPHY; CT; FDG-PET; LABORATORY TEST; LYMPHOMA; METABOLIC INFORMATION; MORPHOLOGICAL IMAGES; MR IMAGING; NON-HODGKIN'S LYMPHOMA; PET IMAGING; STANDARDIZED UPTAKE VALUES; TREATMENT RESPONSE; TUMOR ACTIVITY; TUMOR VOLUMES; VOLUME CHANGE; WHOLE-BODY;

CELL PROLIFERATION; IMAGE SEGMENTATION; MAGNETIC RESONANCE IMAGING; MEDICAL IMAGING; ONCOLOGY; PATIENT TREATMENT; POLYETHYLENE TEREPHTHALATES; POSITRON EMISSION TOMOGRAPHY; TUMORS;

COMPUTERIZED TOMOGRAPHY;

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HODGKIN DISEASE; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SCINTISCANNING; TUMOR VOLUME;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 83155176881     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1258/ar.2011.110099     Document Type: Article

References (34)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
2. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1
3. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6 (Pubitemid 19272832)
4. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65 (Pubitemid 39166497)
5. Christiansen I, Gidlof C, Kälkner KM, et al. Elevated serum levels of soluble ICAM-1 in non-Hodgkin's lymphomas correlate with tumour burden, disease activity and other prognostic markers. Br J Haematol 1996;92:639-46 (Pubitemid 26076765)
6. Federico M, Vitolo U, Zinzani PL, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000;95:783-9 (Pubitemid 30062696)
7. Reinhardt MJ, Herkel C, Altehoefer C, et al. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET? Ann Oncol 2005;16:1524-9 (Pubitemid 41222426)
8. Armitage JO, Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993;328:1023-30 (Pubitemid 23095688)
9. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
10. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031-9
11. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14 (Pubitemid 11167383)
12. Rossi M, Dastidar P, Pertovaara H, et al. Response Analysis of Non-Hodgkin's Lymphoma Using MRI-Based Volumes. J Comput Assist Tomogr 2009;33:466-74
13. Rossi M, Pertovaara H, Dastidar P, et al. CT-Based Tumour Volume in Non-Hodgkin's Lymphoma: Clinical Correlation and Comparison with MRI. J Comput Assist Tomogr 2009;33:641-9
14. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244
15. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991;32:686-91
16. Nguyen XC, Lee WW, Amin AM, et al. Tumour Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma. Nucl Med Mol Imaging 2010;44:39-44
17. Cazaentre T, Morschhauser F, Vermandel M, et al. Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37:494-504
18. Harrison L, Dastidar P, Eskola H, et al. Texture analysis on MRI images of non-Hodgkin lymphoma. Comput Biol Med 2008;38:519-24
19. Harrison LC, Luukkaala T, Pertovaara H, et al. Non-Hodgkin lymphoma response evaluation with MRI texture classification. J Exp Clin Cancer Res 2009;28:87
20. Denecke T, Rau B, Hoffmann KT, et al. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging? Eur Radiol 2005;15:1658-66 (Pubitemid 41102362)
21. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992;33:325-9
22. Lapela M, Leskinen S, Minn HR, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995;86:3522-7
23. Tang B, Malysz J, Douglas-Nikitin V, et al. Correlating metabolic activity with cellular proliferation in follicular lymphomas. Mol Imaging Biol 2009;11:296-302
24. de Wit M, Bohuslavizki KH, Buchert R, et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001;12:29-37 (Pubitemid 32162445)
25. Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al. The prognostic significance of beta (2)-microglobulin in patients with Hodgkin's lymphoma. Haematologica 2002;87:701-8 (Pubitemid 34787140)
26. Jagannath S, Velasquez WS, Tucker SL, et al. Tumour burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 1986;4:859-65 (Pubitemid 16080938)
27. Ha CS, Kong JS, McLaughlin P, et al. Stage III follicular lymphoma: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 2003;57:748-54 (Pubitemid 37194301)
28. Gurkaynak M, Cengiz M, Akyurek S, et al. Waldeyer's ring lymphomas: treatment results and prognostic factors. Am J Clin Oncol 2003;26:437-40 (Pubitemid 37248258)
29. Kwon B, Choi Y, Soel Y, et al. Maximum standardized uptake (SUVmax) on initial 18FDG-PET/CT as prognostic value in patients with diffuse large B-cell lymphoma. J Clin Oncol 2010;28(Suppl. 15): 8103):8103
30. Moore DF Jr, Cabanillas F. Overview of prognostic factors in non-Hodgkin's lymphoma. Oncology 1998;12:17-24 (Pubitemid 128637450)
31. Basu S, Li G, Bural G, et al. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility. Acta Radiol 2009;50:201-4
32. Gardini A, Saragoni L, La Barba G, et al. Simultaneous occurrence of primary diffuse large B-cell lymphoma and extranodal marginal zone (MALT) B-cell lymphoma in the gallbladder: a case report. Pathologica 2009;101:230-4
33. Lichy MP, Aschoff P, Plathow C, et al. Tumour detection by diffusion-weighted MRI and ADC-mapping-initial clinical experiences in comparison to PET-CT. Invest Radiol 2007;42:605-13 (Pubitemid 47262928)
34. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122-50